nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Isoetarine—Salbutamol—chronic obstructive pulmonary disease	0.149	0.178	CrCrCtD
Methyldopa—Norepinephrine—Salbutamol—chronic obstructive pulmonary disease	0.139	0.166	CrCrCtD
Methyldopa—Levonordefrin—Salbutamol—chronic obstructive pulmonary disease	0.131	0.156	CrCrCtD
Methyldopa—Isoprenaline—Formoterol—chronic obstructive pulmonary disease	0.113	0.135	CrCrCtD
Methyldopa—Isoprenaline—Arformoterol—chronic obstructive pulmonary disease	0.113	0.135	CrCrCtD
Methyldopa—Epinephrine—Salbutamol—chronic obstructive pulmonary disease	0.105	0.126	CrCrCtD
Methyldopa—Isoprenaline—Salbutamol—chronic obstructive pulmonary disease	0.0858	0.103	CrCrCtD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA5—chronic obstructive pulmonary disease	0.00357	0.0845	CbGpPWpGaD
Methyldopa—COMT—Methylation—CYP1A2—chronic obstructive pulmonary disease	0.00315	0.0744	CbGpPWpGaD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA3—chronic obstructive pulmonary disease	0.00291	0.0689	CbGpPWpGaD
Methyldopa—Joint swelling—Tiotropium—chronic obstructive pulmonary disease	0.00281	0.025	CcSEcCtD
Methyldopa—Endocrine disorder—Roflumilast—chronic obstructive pulmonary disease	0.00264	0.0235	CcSEcCtD
Methyldopa—COMT—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00197	0.0465	CbGpPWpGaD
Methyldopa—Gynaecomastia—Roflumilast—chronic obstructive pulmonary disease	0.00196	0.0174	CcSEcCtD
Methyldopa—Foetor hepaticus—Montelukast—chronic obstructive pulmonary disease	0.00192	0.0171	CcSEcCtD
Methyldopa—Distention—Prednisone—chronic obstructive pulmonary disease	0.00186	0.0165	CcSEcCtD
Methyldopa—Liver disorder—Montelukast—chronic obstructive pulmonary disease	0.0016	0.0142	CcSEcCtD
Methyldopa—COMT—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00151	0.0356	CbGpPWpGaD
Methyldopa—COMT—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00143	0.0338	CbGpPWpGaD
Methyldopa—Lightheadedness—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.0116	CcSEcCtD
Methyldopa—Liver injury—Montelukast—chronic obstructive pulmonary disease	0.00129	0.0115	CcSEcCtD
Methyldopa—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.00123	0.0109	CcSEcCtD
Methyldopa—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.00123	0.0109	CcSEcCtD
Methyldopa—ADRA2A—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.00118	0.0279	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.0103	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—APIP—chronic obstructive pulmonary disease	0.00116	0.0274	CbGpPWpGaD
Methyldopa—Vasculitis—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00993	CcSEcCtD
Methyldopa—Hepatocellular injury—Montelukast—chronic obstructive pulmonary disease	0.00109	0.00969	CcSEcCtD
Methyldopa—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.00108	0.00962	CcSEcCtD
Methyldopa—DDC—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00105	0.0247	CbGpPWpGaD
Methyldopa—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00102	0.00909	CcSEcCtD
Methyldopa—Nightmare—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00902	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—RAPGEF3—chronic obstructive pulmonary disease	0.000994	0.0235	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000992	0.00882	CcSEcCtD
Methyldopa—Aminosalicylic Acid—MPO—chronic obstructive pulmonary disease	0.000964	0.168	CrCbGaD
Methyldopa—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.000964	0.00858	CcSEcCtD
Methyldopa—Lightheadedness—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00836	CcSEcCtD
Methyldopa—Cardiac failure congestive—Formoterol—chronic obstructive pulmonary disease	0.00089	0.00792	CcSEcCtD
Methyldopa—Cardiac failure congestive—Arformoterol—chronic obstructive pulmonary disease	0.00089	0.00792	CcSEcCtD
Methyldopa—Nasal congestion—Formoterol—chronic obstructive pulmonary disease	0.000886	0.00789	CcSEcCtD
Methyldopa—Nasal congestion—Arformoterol—chronic obstructive pulmonary disease	0.000886	0.00789	CcSEcCtD
Methyldopa—Eczema—Montelukast—chronic obstructive pulmonary disease	0.00088	0.00783	CcSEcCtD
Methyldopa—Isoetarine—ADRB2—chronic obstructive pulmonary disease	0.000874	0.153	CrCbGaD
Methyldopa—Eczema—Salbutamol—chronic obstructive pulmonary disease	0.000848	0.00755	CcSEcCtD
Methyldopa—Angina pectoris—Tiotropium—chronic obstructive pulmonary disease	0.000842	0.00749	CcSEcCtD
Methyldopa—Nasal congestion—Salbutamol—chronic obstructive pulmonary disease	0.000837	0.00745	CcSEcCtD
Methyldopa—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.000815	0.00726	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00081	0.00721	CcSEcCtD
Methyldopa—Infection—Roflumilast—chronic obstructive pulmonary disease	0.000777	0.00691	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000768	0.0182	CbGpPWpGaD
Methyldopa—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.000767	0.00682	CcSEcCtD
Methyldopa—DDC—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00076	0.018	CbGpPWpGaD
Methyldopa—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000759	0.00676	CcSEcCtD
Methyldopa—Mesalazine—MPO—chronic obstructive pulmonary disease	0.000757	0.132	CrCbGaD
Methyldopa—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000712	0.00634	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Montelukast—chronic obstructive pulmonary disease	0.000712	0.00634	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000694	0.0164	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.00068	0.00605	CcSEcCtD
Methyldopa—Angina pectoris—Arformoterol—chronic obstructive pulmonary disease	0.00068	0.00605	CcSEcCtD
Methyldopa—Angina pectoris—Formoterol—chronic obstructive pulmonary disease	0.00068	0.00605	CcSEcCtD
Methyldopa—Eosinophilia—Montelukast—chronic obstructive pulmonary disease	0.000677	0.00602	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000675	0.00601	CcSEcCtD
Methyldopa—Pancreatitis—Montelukast—chronic obstructive pulmonary disease	0.00067	0.00596	CcSEcCtD
Methyldopa—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000668	0.00595	CcSEcCtD
Methyldopa—COMT—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000665	0.0157	CbGpPWpGaD
Methyldopa—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000663	0.0059	CcSEcCtD
Methyldopa—COMT—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000657	0.0155	CbGpPWpGaD
Methyldopa—Angina pectoris—Salbutamol—chronic obstructive pulmonary disease	0.000642	0.00571	CcSEcCtD
Methyldopa—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.000628	0.00559	CcSEcCtD
Methyldopa—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000624	0.00555	CcSEcCtD
Methyldopa—Vasculitis—Prednisolone—chronic obstructive pulmonary disease	0.000617	0.00549	CcSEcCtD
Methyldopa—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000609	0.00542	CcSEcCtD
Methyldopa—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000609	0.00542	CcSEcCtD
Methyldopa—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.000606	0.00539	CcSEcCtD
Methyldopa—Jaundice—Montelukast—chronic obstructive pulmonary disease	0.000594	0.00529	CcSEcCtD
Methyldopa—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.000576	0.00513	CcSEcCtD
Methyldopa—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000576	0.00513	CcSEcCtD
Methyldopa—Jaundice—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.00509	CcSEcCtD
Methyldopa—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000561	0.00499	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—RAPGEF3—chronic obstructive pulmonary disease	0.000553	0.0131	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.000552	0.0131	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000549	0.00488	CcSEcCtD
Methyldopa—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000549	0.00488	CcSEcCtD
Methyldopa—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000547	0.00487	CcSEcCtD
Methyldopa—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000537	0.00478	CcSEcCtD
Methyldopa—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000535	0.00476	CcSEcCtD
Methyldopa—Endocrine disorder—Prednisone—chronic obstructive pulmonary disease	0.000528	0.0047	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000523	0.0124	CbGpPWpGaD
Methyldopa—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000518	0.00461	CcSEcCtD
Methyldopa—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000518	0.00461	CcSEcCtD
Methyldopa—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000518	0.00461	CcSEcCtD
Methyldopa—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000518	0.00461	CcSEcCtD
Methyldopa—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000517	0.0046	CcSEcCtD
Methyldopa—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000513	0.00456	CcSEcCtD
Methyldopa—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000513	0.00456	CcSEcCtD
Methyldopa—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000511	0.00455	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000509	0.00453	CcSEcCtD
Methyldopa—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000508	0.00452	CcSEcCtD
Methyldopa—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000503	0.00448	CcSEcCtD
Methyldopa—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000503	0.00448	CcSEcCtD
Methyldopa—Amenorrhoea—Prednisone—chronic obstructive pulmonary disease	0.000498	0.00443	CcSEcCtD
Methyldopa—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000497	0.00442	CcSEcCtD
Methyldopa—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000493	0.00439	CcSEcCtD
Methyldopa—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000493	0.00439	CcSEcCtD
Methyldopa—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000492	0.00438	CcSEcCtD
Methyldopa—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000492	0.00437	CcSEcCtD
Methyldopa—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00049	0.00436	CcSEcCtD
Methyldopa—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000489	0.00435	CcSEcCtD
Methyldopa—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000489	0.00435	CcSEcCtD
Methyldopa—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000489	0.00435	CcSEcCtD
Methyldopa—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000488	0.00435	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000482	0.0114	CbGpPWpGaD
Methyldopa—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000482	0.00429	CcSEcCtD
Methyldopa—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.000482	0.00429	CcSEcCtD
Methyldopa—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000479	0.00426	CcSEcCtD
Methyldopa—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000478	0.00426	CcSEcCtD
Methyldopa—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000477	0.00425	CcSEcCtD
Methyldopa—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00423	CcSEcCtD
Methyldopa—DDC—respiratory system—chronic obstructive pulmonary disease	0.000474	0.196	CbGeAlD
Methyldopa—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000464	0.00413	CcSEcCtD
Methyldopa—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000462	0.00411	CcSEcCtD
Methyldopa—COMT—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.000461	0.0109	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.00046	0.0109	CbGpPWpGaD
Methyldopa—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00403	CcSEcCtD
Methyldopa—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000448	0.00399	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000448	0.00399	CcSEcCtD
Methyldopa—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000441	0.00393	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000435	0.0103	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000435	0.0103	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000426	0.0101	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000424	0.00378	CcSEcCtD
Methyldopa—COMT—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.000423	0.01	CbGpPWpGaD
Methyldopa—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00042	0.00374	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000418	0.00987	CbGpPWpGaD
Methyldopa—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000414	0.00368	CcSEcCtD
Methyldopa—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000414	0.00368	CcSEcCtD
Methyldopa—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000414	0.00368	CcSEcCtD
Methyldopa—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000414	0.00368	CcSEcCtD
Methyldopa—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000412	0.00367	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000411	0.00366	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000411	0.00366	CcSEcCtD
Methyldopa—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000405	0.00361	CcSEcCtD
Methyldopa—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000405	0.00361	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—GCLC—chronic obstructive pulmonary disease	0.000403	0.00954	CbGpPWpGaD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000403	0.00358	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000402	0.00951	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000401	0.00947	CbGpPWpGaD
Methyldopa—Droxidopa—ADRB2—chronic obstructive pulmonary disease	0.000399	0.0697	CrCbGaD
Methyldopa—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000397	0.00353	CcSEcCtD
Methyldopa—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000397	0.00353	CcSEcCtD
Methyldopa—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000394	0.00351	CcSEcCtD
Methyldopa—Infection—Formoterol—chronic obstructive pulmonary disease	0.000394	0.00351	CcSEcCtD
Methyldopa—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00348	CcSEcCtD
Methyldopa—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00348	CcSEcCtD
Methyldopa—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.00346	CcSEcCtD
Methyldopa—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000389	0.00346	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000389	0.0092	CbGpPWpGaD
Methyldopa—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000389	0.00346	CcSEcCtD
Methyldopa—Infection—Montelukast—chronic obstructive pulmonary disease	0.000386	0.00344	CcSEcCtD
Methyldopa—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000385	0.00343	CcSEcCtD
Methyldopa—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.00343	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000384	0.00909	CbGpPWpGaD
Methyldopa—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000384	0.00342	CcSEcCtD
Methyldopa—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000381	0.00339	CcSEcCtD
Methyldopa—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00038	0.00339	CcSEcCtD
Methyldopa—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00038	0.00338	CcSEcCtD
Methyldopa—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000377	0.00336	CcSEcCtD
Methyldopa—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.00333	CcSEcCtD
Methyldopa—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000372	0.00331	CcSEcCtD
Methyldopa—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.00037	0.0033	CcSEcCtD
Methyldopa—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.00327	CcSEcCtD
Methyldopa—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00324	CcSEcCtD
Methyldopa—Isoprenaline—ADRB2—chronic obstructive pulmonary disease	0.000363	0.0634	CrCbGaD
Methyldopa—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000362	0.00322	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00322	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00322	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000358	0.00848	CbGpPWpGaD
Methyldopa—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000357	0.00317	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000355	0.0084	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000354	0.00315	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000351	0.0083	CbGpPWpGaD
Methyldopa—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.00035	0.00312	CcSEcCtD
Methyldopa—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000349	0.00311	CcSEcCtD
Methyldopa—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000345	0.00307	CcSEcCtD
Methyldopa—Epinephrine—TNF—chronic obstructive pulmonary disease	0.000344	0.0601	CrCbGaD
Methyldopa—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000344	0.00306	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00305	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00305	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00304	CcSEcCtD
Methyldopa—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00302	CcSEcCtD
Methyldopa—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00302	CcSEcCtD
Methyldopa—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00299	CcSEcCtD
Methyldopa—Norepinephrine—ADRB2—chronic obstructive pulmonary disease	0.000336	0.0587	CrCbGaD
Methyldopa—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000335	0.00299	CcSEcCtD
Methyldopa—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000331	0.00295	CcSEcCtD
Methyldopa—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000329	0.00292	CcSEcCtD
Methyldopa—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000328	0.00292	CcSEcCtD
Methyldopa—COMT—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000327	0.00772	CbGpPWpGaD
Methyldopa—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000327	0.00291	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000326	0.00772	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000326	0.00772	CbGpPWpGaD
Methyldopa—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000325	0.00289	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000325	0.00769	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.00288	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000323	0.00764	CbGpPWpGaD
Methyldopa—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00285	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000319	0.00754	CbGpPWpGaD
Methyldopa—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000314	0.00279	CcSEcCtD
Methyldopa—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000314	0.00279	CcSEcCtD
Methyldopa—COMT—respiratory system—chronic obstructive pulmonary disease	0.000313	0.129	CbGeAlD
Methyldopa—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000313	0.00278	CcSEcCtD
Methyldopa—Isoprenaline—CYP1A1—chronic obstructive pulmonary disease	0.000311	0.0543	CrCbGaD
Methyldopa—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.00031	0.00276	CcSEcCtD
Methyldopa—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00031	0.00276	CcSEcCtD
Methyldopa—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00031	0.00276	CcSEcCtD
Methyldopa—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00031	0.00276	CcSEcCtD
Methyldopa—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00274	CcSEcCtD
Methyldopa—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000308	0.00274	CcSEcCtD
Methyldopa—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000307	0.00273	CcSEcCtD
Methyldopa—Epinephrine—ADRB2—chronic obstructive pulmonary disease	0.000305	0.0533	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000302	0.00713	CbGpPWpGaD
Methyldopa—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000296	0.00264	CcSEcCtD
Methyldopa—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000292	0.0026	CcSEcCtD
Methyldopa—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000292	0.0026	CcSEcCtD
Methyldopa—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000292	0.0026	CcSEcCtD
Methyldopa—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000286	0.00255	CcSEcCtD
Methyldopa—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000285	0.00253	CcSEcCtD
Methyldopa—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.00253	CcSEcCtD
Methyldopa—Dopamine—SLC6A4—chronic obstructive pulmonary disease	0.000284	0.0495	CrCbGaD
Methyldopa—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000279	0.00248	CcSEcCtD
Methyldopa—Norepinephrine—CYP1A2—chronic obstructive pulmonary disease	0.000278	0.0485	CrCbGaD
Methyldopa—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00246	CcSEcCtD
Methyldopa—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.00246	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000274	0.00649	CbGpPWpGaD
Methyldopa—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00242	CcSEcCtD
Methyldopa—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00242	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.00027	0.00637	CbGpPWpGaD
Methyldopa—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000269	0.0024	CcSEcCtD
Methyldopa—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.00239	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000267	0.00631	CbGpPWpGaD
Methyldopa—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00237	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000266	0.00629	CbGpPWpGaD
Methyldopa—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00233	CcSEcCtD
Methyldopa—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00233	CcSEcCtD
Methyldopa—Dopamine—CYP1A2—chronic obstructive pulmonary disease	0.000258	0.0451	CrCbGaD
Methyldopa—COMT—bronchus—chronic obstructive pulmonary disease	0.000258	0.107	CbGeAlD
Methyldopa—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00229	CcSEcCtD
Methyldopa—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00228	CcSEcCtD
Methyldopa—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000253	0.00225	CcSEcCtD
Methyldopa—COMT—smooth muscle tissue—chronic obstructive pulmonary disease	0.000252	0.104	CbGeAlD
Methyldopa—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000252	0.00224	CcSEcCtD
Methyldopa—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.00224	CcSEcCtD
Methyldopa—Epinephrine—CYP1A2—chronic obstructive pulmonary disease	0.000252	0.044	CrCbGaD
Methyldopa—DDC—lung—chronic obstructive pulmonary disease	0.000252	0.104	CbGeAlD
Methyldopa—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00223	CcSEcCtD
Methyldopa—Rash—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00223	CcSEcCtD
Methyldopa—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00222	CcSEcCtD
Methyldopa—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00222	CcSEcCtD
Methyldopa—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00025	0.00222	CcSEcCtD
Methyldopa—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00221	CcSEcCtD
Methyldopa—Headache—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00221	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000248	0.00586	CbGpPWpGaD
Methyldopa—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.0022	CcSEcCtD
Methyldopa—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000247	0.0022	CcSEcCtD
Methyldopa—Rash—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00218	CcSEcCtD
Methyldopa—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00218	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000244	0.00578	CbGpPWpGaD
Methyldopa—Headache—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00217	CcSEcCtD
Methyldopa—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00212	CcSEcCtD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	0.000238	0.00563	CbGpPWpGaD
Methyldopa—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.0021	CcSEcCtD
Methyldopa—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.0021	CcSEcCtD
Methyldopa—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.0021	CcSEcCtD
Methyldopa—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000236	0.0021	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000235	0.00555	CbGpPWpGaD
Methyldopa—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00209	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000232	0.00548	CbGpPWpGaD
Methyldopa—COMT—trachea—chronic obstructive pulmonary disease	0.000232	0.0957	CbGeAlD
Methyldopa—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000231	0.00205	CcSEcCtD
Methyldopa—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000224	0.00199	CcSEcCtD
Methyldopa—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00198	CcSEcCtD
Methyldopa—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00192	CcSEcCtD
Methyldopa—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000215	0.00191	CcSEcCtD
Methyldopa—DDC—Metabolism—APIP—chronic obstructive pulmonary disease	0.000213	0.00503	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000203	0.00479	CbGpPWpGaD
Methyldopa—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000199	0.00177	CcSEcCtD
Methyldopa—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000193	0.00172	CcSEcCtD
Methyldopa—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000193	0.00171	CcSEcCtD
Methyldopa—COMT—Metabolism—APIP—chronic obstructive pulmonary disease	0.000189	0.00447	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000189	0.00447	CbGpPWpGaD
Methyldopa—COMT—lung—chronic obstructive pulmonary disease	0.000166	0.0687	CbGeAlD
Methyldopa—DDC—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000165	0.0039	CbGpPWpGaD
Methyldopa—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00145	CcSEcCtD
Methyldopa—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00145	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00144	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.000159	0.00376	CbGpPWpGaD
Methyldopa—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000158	0.00141	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000158	0.00374	CbGpPWpGaD
Methyldopa—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000156	0.00139	CcSEcCtD
Methyldopa—Infection—Prednisone—chronic obstructive pulmonary disease	0.000155	0.00138	CcSEcCtD
Methyldopa—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00136	CcSEcCtD
Methyldopa—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00135	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000142	0.00127	CcSEcCtD
Methyldopa—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00126	CcSEcCtD
Methyldopa—DDC—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000141	0.00333	CbGpPWpGaD
Methyldopa—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.00014	0.058	CbGeAlD
Methyldopa—ADRA2A—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.00014	0.00332	CbGpPWpGaD
Methyldopa—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00125	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000138	0.00327	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GC—chronic obstructive pulmonary disease	0.000137	0.00324	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	0.000137	0.00323	CbGpPWpGaD
Methyldopa—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.00121	CcSEcCtD
Methyldopa—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.0012	CcSEcCtD
Methyldopa—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.0012	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000134	0.00317	CbGpPWpGaD
Methyldopa—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00119	CcSEcCtD
Methyldopa—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.000131	0.0543	CbGeAlD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000128	0.00304	CbGpPWpGaD
Methyldopa—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.00114	CcSEcCtD
Methyldopa—DDC—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000127	0.00301	CbGpPWpGaD
Methyldopa—COMT—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000125	0.00296	CbGpPWpGaD
Methyldopa—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000123	0.0011	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000123	0.0029	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GC—chronic obstructive pulmonary disease	0.000122	0.00288	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	0.000119	0.0028	CbGpPWpGaD
Methyldopa—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000118	0.0487	CbGeAlD
Methyldopa—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00102	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000115	0.00272	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000113	0.00268	CbGpPWpGaD
Methyldopa—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000997	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00011	0.0026	CbGpPWpGaD
Methyldopa—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000951	CcSEcCtD
Methyldopa—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000919	CcSEcCtD
Methyldopa—Vomiting—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000883	CcSEcCtD
Methyldopa—Rash—Prednisone—chronic obstructive pulmonary disease	9.84e-05	0.000876	CcSEcCtD
Methyldopa—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.83e-05	0.000875	CcSEcCtD
Methyldopa—Headache—Prednisone—chronic obstructive pulmonary disease	9.78e-05	0.00087	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	9.32e-05	0.0022	CbGpPWpGaD
Methyldopa—Nausea—Prednisone—chronic obstructive pulmonary disease	9.27e-05	0.000825	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	9.26e-05	0.00219	CbGpPWpGaD
Methyldopa—ADRA2A—lung—chronic obstructive pulmonary disease	8.47e-05	0.035	CbGeAlD
Methyldopa—ADRA2A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	8.38e-05	0.00198	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	8.26e-05	0.00195	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	8.06e-05	0.00191	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	7.89e-05	0.00187	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	7.56e-05	0.00179	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APIP—chronic obstructive pulmonary disease	7.51e-05	0.00178	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.49e-05	0.00177	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GCLC—chronic obstructive pulmonary disease	7.4e-05	0.00175	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	7.05e-05	0.00167	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	6.9e-05	0.00163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	6.86e-05	0.00162	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CTGF—chronic obstructive pulmonary disease	6.76e-05	0.0016	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.65e-05	0.00157	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GCLC—chronic obstructive pulmonary disease	6.57e-05	0.00155	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.3e-05	0.00149	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.23e-05	0.00147	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	6.17e-05	0.00146	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	6.11e-05	0.00144	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CTGF—chronic obstructive pulmonary disease	6e-05	0.00142	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.88e-05	0.00139	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.53e-05	0.00131	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	5.48e-05	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.4e-05	0.00128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.34e-05	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.26e-05	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	5.2e-05	0.00123	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.19e-05	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	5.19e-05	0.00123	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.12e-05	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.97e-05	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	4.94e-05	0.00117	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	4.84e-05	0.00114	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.77e-05	0.00113	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.74e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.74e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.7e-05	0.00111	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.61e-05	0.00109	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.55e-05	0.00108	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.52e-05	0.00107	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.5e-05	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.3e-05	0.00102	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.24e-05	0.001	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.19e-05	0.000992	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.16e-05	0.000984	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.11e-05	0.000972	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.02e-05	0.00095	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.58e-05	0.000846	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.53e-05	0.000835	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.47e-05	0.00082	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.33e-05	0.000789	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.28e-05	0.000777	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.18e-05	0.000753	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.15e-05	0.000745	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—chronic obstructive pulmonary disease	3.07e-05	0.000727	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.97e-05	0.000703	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—chronic obstructive pulmonary disease	2.94e-05	0.000695	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—chronic obstructive pulmonary disease	2.73e-05	0.000646	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.7e-05	0.000638	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.68e-05	0.000634	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	2.68e-05	0.000633	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.65e-05	0.000628	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.64e-05	0.000625	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	2.61e-05	0.000618	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—chronic obstructive pulmonary disease	2.61e-05	0.000618	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.56e-05	0.000605	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.54e-05	0.000601	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.54e-05	0.0006	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.41e-05	0.00057	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	2.38e-05	0.000564	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.32e-05	0.000549	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.2e-05	0.000519	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.11e-05	0.000499	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.86e-05	0.000439	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.84e-05	0.000436	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.83e-05	0.000433	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.81e-05	0.000427	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.73e-05	0.000408	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.69e-05	0.0004	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.68e-05	0.000398	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.6e-05	0.000377	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.59e-05	0.000377	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.43e-05	0.000339	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.42e-05	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.39e-05	0.00033	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.3e-05	0.000308	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.29e-05	0.000306	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.25e-05	0.000295	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.16e-05	0.000274	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	1.08e-05	0.000257	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	1.04e-05	0.000245	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.52e-06	0.000225	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.09e-06	0.000215	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.68e-06	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.7e-06	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.32e-06	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.96e-06	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.25e-06	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.74e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.63e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.72e-06	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.32e-06	0.000102	CbGpPWpGaD
